Harry Doernberg

Aug 21, 2024 | jamanetwork.com | Joshua D. Wallach |Joseph S. Ross |Samuel Yoon |Harry Doernberg

Surrogate Markers and Clinical Outcomes—Reply Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments Joshua D. Wallach, PhD, MS; Samuel Yoon, BS, BA; Harry Doernberg, MM; Laura R. Glick, MD; Oriana Ciani, PhD; Rod S. Taylor, PhD; Maryam Mooghali, MD; Reshma Ramachandran, MD, MHS, MPP; Joseph S.

Apr 22, 2024 | jamanetwork.com | Joshua D. Wallach |Samuel Yoon |Harry Doernberg |Laura R Glick

Associations Between Surrogate Markers and Clinical Outcomes for Nononcologic Chronic Disease Treatments Key PointsQuestion  What is the strength of association between surrogate markers used as primary end points in clinical trials to support Food and Drug Administration (FDA) approval of drugs treating nononcologic chronic diseases and clinical outcomes?

Mar 15, 2024 | jamanetwork.com | Harry Doernberg

I started playing cello when I was very young, before I can remember almost anything else. These days, medical school and its commitments mean I don’t get an opportunity to play much anymore. But the instrument has left its imprint on me—the fingers on my left hand are a centimeter longer than those on the right; the right index finger skews to the side. Back as a music graduate student, I used to give cello lessons to students with varying experience.